^
    9d
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)
    15d
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Centre Leon Berard | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)
    24d
    MIBG for Refractory Neuroblastoma and Pheochromocytoma (clinicaltrials.gov)
    P=N/A, N=15, Completed, Masonic Cancer Center, University of Minnesota | Suspended --> Completed | N=100 --> 15
    Trial completion • Enrollment change
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2)
    |
    Neulasta (pegfilgrastim) • Azedra (iobenguane I 131)
    1m
    Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, University of Washington
    New P2 trial
    |
    Rituxan (rituximab) • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    1m
    Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov)
    P3, N=1174, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov)
    P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jul 2025 --> Dec 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • sorafenib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dactinomycin • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • dexrazoxane
    2ms
    Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    Neulasta (pegfilgrastim) • captisol-enabled melphalan
    2ms
    GCSF-PAIN: G-CSF-Induced Bone Pain and Supportive Care Approaches (clinicaltrials.gov)
    P=N/A, N=128, Recruiting, Ankara Etlik City Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Neulasta (pegfilgrastim) • Lonquex (lipegfilgrastim) • Neupogen (filgrastim)
    2ms
    GCSF-PAIN: G-CSF-Induced Bone Pain and Supportive Care Approaches (clinicaltrials.gov)
    P=N/A, N=128, Not yet recruiting, Ankara Etlik City Hospital
    New trial
    |
    Neulasta (pegfilgrastim) • Lonquex (lipegfilgrastim) • Neupogen (filgrastim)
    2ms
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov)
    P2/3, N=600, Terminated, Sutro Biopharma, Inc. | Trial completion date: Feb 2028 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Aug 2025; Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety or efficacy concerns associated with luvelta
    Trial completion date • Trial termination • Trial primary completion date • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression • FOLR1 positive
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
    2ms
    ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Michael Spinner, MD | Initiation date: Jul 2025 --> Oct 2025
    Trial initiation date • Circulating tumor DNA
    |
    Foresight CLARITY™
    |
    Keytruda (pembrolizumab) • gemcitabine • pegylated liposomal doxorubicin • Neulasta (pegfilgrastim)
    3ms
    Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=17, Completed, University of Washington | Trial completion date: Oct 2025 --> Mar 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • cisplatin • doxorubicin hydrochloride • methotrexate • daunorubicin • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • methotrexate IV